Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: de Botton, S, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Ommen, H, Semochkin, S, Kim, H-J, Larson, RA, Koprivnikar, J, Frankfurt, O, Thol, F, Chromik, J, Byrne, J, Pigneux, A, Thomas, X, Salamero, O, Vidriales, MB, Doronin, V, Döhner, H, Fathi, AT, Laille, E, Yu, X, Hasan, M, Martin-Regueira, P, DiNardo, CD
स्वरूप: Journal article
भाषा:English
प्रकाशित: American Society of Hematology 2022

समान संसाधन